Summary of clinically relevant or commonly used amylin-related peptides and their effects
Sequences are shown in Fig. 3.
| Peptide | Alternative Names | Agonist/Antagonist | Pharmacology |
|---|---|---|---|
| Pramlintide | Symlin, tripro-amylin (human), [Pro25,28,29]amylin (human), AC137 | Agonist | Modified human amylin that lacks amyloidogenic properties; approved in the United States for clinical treatment of type 1 and type 2 diabetes; exhibits similar pharmacology and pharmacokinetic properties to nonamyloidogenic rat amylin. Pharmacology at molecularly defined amylin receptors shows close similarity to human and rat amylin (Gingell et al., 2014) |
| Davalintide | AC2307 | Agonist | Longer-acting amylin agonist optimized for therapeutic treatment of obesity (Mack et al., 2010). Binds with high affinity to rat nucleus accumbens amylin and calcitonin receptors. Pharmacology at molecularly defined amylin receptors has not been reported |
| AC187 | Antagonist | Used as a pharmacological tool to block endogenous actions of amylin. Receptor pharmacology studies show that this peptide can antagonize both calcitonin and amylin receptors (Hay et al., 2005) | |
| AC253 | [Arg4,11]AC187 | Antagonist | Similar to AC187, AC253 has been used to block endogenous actions of amylin (Mather et al., 2002). Receptor pharmacology studies show that this peptide can antagonize rat nucleus accumbens amylin and calcitonin receptors. Pharmacology at molecularly defined amylin receptors has not been reported |
| Salmon calcitonin 8-32 | AC66 | Antagonist | Used as a pharmacological tool to block endogenous actions of amylin. Receptor pharmacology studies show that this peptide can antagonize both calcitonin and amylin receptors (Hay et al., 2005) |